RMC Biosciences

Revolution Medicines is a clinical-stage oncology company focused on developing novel therapies for RAS-addicted cancers. The company's proprietary platform is designed to discover and develop "RAS(ON)" inhibitors, which target the active, GTP-bound form of RAS proteins, offering a potential advantage over first-generation RAS(OFF) inhibitors. Their lead candidate, RMC-6236, is a first-in-class RAS-MULTI(ON) inhibitor currently in late-stage clinical development for pancreatic and lung cancers. The pipeline also includes mutation-specific inhibitors such as RMC-6291 (KRAS G12C) and RMC-9805 (KRAS G12D), as well as inhibitors of upstream regulators like SHP2. Revolution Medicines aims to address the high unmet need in patients with RAS-driven tumors through both monotherapy and rational combination strategies.